Following priority review, the U.S. Food and Drug Administration approved Bayer's Kerendia (finerenone) for the treatment of ...

Following priority review, the FDA approved Kerendia for the treatment of patients with heart failure with left ventricular ejection fraction (LVEF) ≥40%.

Finerenone gained FDA approval for heart failure treatment, showcasing significant benefits in reducing cardiovascular events ...

The FDA expanded the indication for finerenone (Kerendia) in heart failure (HF), drug manufacturer Bayer announced.

Figure 1. Heart failure with normal ejection fraction guidelines. Ad: Duration of mitral valve atrial wave flow; Ard: Duration of reverse pulmonary vein atrial systole flow; DT: Deceleration time ...

Given the current trends, heart failure with normal ejection fraction will become the most common form of heart failure, for which we do not currently have an evidence-based successful treatment.

There are consistent associations between elevated urinary metal levels and increased HF risk over time across geographically diverse cohorts of adults.

The era of predictive modeling enhanced with machine learning and artificial intelligence (AI) to aid clinical ...

The US Food and Drug Administration (FDA) has granted 510 (k) clearance for Tempus AI’s ECG-Low (ejection fraction) EF software. This software utilises AI to detect individuals with a low left ...

The US Food and Drug Administration has approved the use of finerenone (Kerendia) in heart failure (HF) patients with mildly ...

CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, announced today that the Centers for Medicare and Medicaid Services (CMS) ...